Medtronic “Repurposes” Spine Convention Booth To Tell Its Side of BMP Story
Executive Summary
The firm’s bare-bones booth at the North American Spine Society annual meeting was a conspicuous sign of strains between Medtronic and the clinical group over how issues surrounding its rhBMP-2 Infuse bone graft have been presented.
You may also be interested in...
INFUSE Review Leads To Discussion And Some Discord At NASS
Medtronic’s subdued showing at NASS in October revealed the sometimes rocky relationship among industry, clinicians, and academia: The Yale University Open Data Access Project suggested rhBMP-2 didn’t fuse bone any better than standard-iliac crest bone graft, yet Medtronic executives found some vindication in the process, saying it supported on-label use of BMP, and suggested the Yale University-led process could be a model to settle future controversies in the medical industry.
No Advantage For Medtronic’s InFuse Versus Bone Graft In Spine Fusion
The long-awaited independent analysis of clinical data on Medtronic’s InFuse recombinant human bone morphogenetic protein-2 (rhBMP-2) found no advantages to using it as a substitute for traditional bone grafts in spinal fusion surgery, while also revealing that the risks of rhBMP-2 may be greater than has been previously reported.
PODs Alert: HHS Inspector General Issues Fraud Warning For Physician-Owned Device Distributors
The March 26 special fraud alert reiterates the HHS watchdog’s “longstanding position that the opportunity for a referring physician to earn a profit, including through an investment in an entity for which he or she generates business, could constitute illegal remuneration under the anti-kickback statute.”